HBV
MCID: HPT016
MIFTS: 59

Hepatitis B (HBV)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis B

MalaCards integrated aliases for Hepatitis B:

Name: Hepatitis B 12 74 54 42 43 15 37 71
Hepatitis B Infection 12 15
Hepatitis B, Chronic 71
Chronic Hepatitis B 12
Hepatitis B Chronic 54
Serum Hepatitis 12
Hbv 47

Classifications:



External Ids:

Disease Ontology 12 DOID:2043
MeSH 43 D006509
NCIt 49 C3097
SNOMED-CT 67 66071002
UMLS 71 C0019163 C0524909

Summaries for Hepatitis B

MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis B, is caused by the hepatitis B virus (HBV). Hepatitis B spreads by contact with an infected person's blood, semen, or other body fluid. An infected woman can give hepatitis B to her baby at birth. If you get HBV, you may feel as if you have the flu. You may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. Some people have no symptoms at all. A blood test can tell if you have it. HBV usually gets better on its own after a few months. If it does not get better, it is called chronic HBV, which lasts a lifetime. Chronic HBV can lead to cirrhosis (scarring of the liver), liver failure, or liver cancer. There is a vaccine for HBV. It requires three shots. All babies should get the vaccine, but older children and adults can get it too. If you travel to countries where Hepatitis B is common, you should get the vaccine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis B, also known as hepatitis b infection, is related to hepatitis d and liver disease, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis B is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Human cytomegalovirus infection and Immune response Role of DAP12 receptors in NK cells. The drugs glycyrrhizin and Alprostadil have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells.

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis B virus, which is transmitted by sexual contact, transmitted by blood transfusions, and transmitted by fomites like needles or syringes. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 74 Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver; it is... more...

Related Diseases for Hepatitis B

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis B via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1196)
# Related Disease Score Top Affiliating Genes
1 hepatitis d 34.0 IFNA2 IFNA1 GPT F2
2 liver disease 33.1 TNF SLC10A1 IFNA2 IFNA1 GPT F2
3 viral hepatitis 33.0 TNF PTMA IFNA2 IFNA1 GPT F2
4 hepatitis 32.9 TNF SLC10A1 RSF1 NR5A2 MBL2 LAMTOR5
5 liver cirrhosis 32.5 IFNA1 GPT F2 AFP
6 hepatitis c 32.2 TNF IFNAR2 IFNA2 IFNA1 GPT AFP
7 immune deficiency disease 32.0 TNF MBL2 IFNA1 GPT APOBEC3G
8 syphilis 32.0 TNF GPT F2
9 human immunodeficiency virus infectious disease 31.9 TNF MBL2 IFNA1 APOBEC3G
10 hepatitis a 31.9 TNF IFNA2 IFNA1 GPT F2 AFP
11 hepatitis e 31.8 TNF GPT F2
12 viral infectious disease 31.8 TNF IFNAR2 IFNA2 IFNA1 GPT
13 rubella 31.7 TNF IFNAR2 GPT
14 cryoglobulinemia 31.7 TNF IFNA2 IFNA1 GPT
15 hepatic coma 31.7 GPT F2 AFP
16 hepatic encephalopathy 31.6 TNF GPT F2 AFP
17 schistosomiasis 31.5 TNF GPT F2
18 portal hypertension 31.5 TNF GPT F2
19 autoimmune hepatitis 31.5 TNF IFNA1 GPT F2
20 cryoglobulinemia, familial mixed 31.5 IFNA2 IFNA1
21 cholestasis 31.4 TNF SLC10A1 GPT F2
22 mumps 31.4 TNF IFNAR2 IFNA1
23 exanthem 31.4 TNF IFNA1 GPT F2
24 neutropenia 31.4 TNF MBL2 IFNA2 IFNA1 GPT
25 severe acute respiratory syndrome 31.3 TNF MBL2 IFNA1 GPT
26 esophageal varix 31.3 GPT F2 AFP
27 hepatorenal syndrome 31.3 GPT F2 AFP
28 thrombocytopenia 31.3 TNF MBL2 IFNA2 IFNA1 GPT F2
29 stomatitis 31.3 TNF IFNA2 IFNA1
30 cholangitis 31.1 TNF GPT F2
31 hypothyroidism 31.1 TNF IFNA2 IFNA1 GPT F2
32 portal vein thrombosis 31.1 IFNA2 IFNA1 F2 AFP
33 alcoholic hepatitis 31.0 TNF GPT F2
34 bilirubin metabolic disorder 31.0 GPT F2 AFP
35 hepatocellular carcinoma 31.0 TNF RSF1 MIR301A MIR21 MIR17 IFNAR2
36 herpes zoster 31.0 TNF IFNA2 IFNA1
37 drug-induced hepatitis 30.9 TNF GPT F2
38 biliary atresia 30.9 TNF SLC10A1 GPT F2
39 alcoholic liver cirrhosis 30.8 TNF GPT F2 AFP
40 sclerosing cholangitis 30.8 TNF GPT F2
41 placenta disease 30.7 TNF F2 AFP
42 diarrhea 30.7 TNF IFNA2 IFNA1 GPT
43 pyelonephritis 30.7 TNF MBL2 GPT
44 obstructive jaundice 30.7 TNF GPT F2
45 typhoid fever 30.7 TNF GPT F2
46 non-alcoholic steatohepatitis 30.7 TNF MIR21 GPT
47 dengue disease 30.6 TNF MBL2 IFNA1
48 cholangitis, primary sclerosing 30.6 TNF SLC10A1 GPT F2 AFP
49 disseminated intravascular coagulation 30.5 TNF GPT F2
50 essential thrombocythemia 30.5 TNF IFNA2 IFNA1 F2

Graphical network of the top 20 diseases related to Hepatitis B:



Diseases related to Hepatitis B

Symptoms & Phenotypes for Hepatitis B

Symptoms:

12
  • vomiting
  • fatigue
  • fever
  • abdominal pain
  • jaundice
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

UMLS symptoms related to Hepatitis B:


fever, pruritus, nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

Drugs & Therapeutics for Hepatitis B

Drugs for Hepatitis B (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 540)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
2
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
3
Atorvastatin Approved Phase 4 134523-00-5 60823
4
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
5
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
6
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
7
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
8
Racepinephrine Approved Phase 4 329-65-7 838
9
Simethicone Approved Phase 4 8050-81-5
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Ribavirin Approved Phase 4 36791-04-5 37542
14
Cobicistat Approved Phase 4 1004316-88-4
15
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
16
Zidovudine Approved Phase 4 30516-87-1 35370
17
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
18
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
19
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
20
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
21
Pentetic acid Approved Phase 4 67-43-6
22
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
23
Azathioprine Approved Phase 4 446-86-6 2265
24
Etanercept Approved, Investigational Phase 4 185243-69-0
25
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
26
Saxagliptin Approved Phase 4 361442-04-8 11243969
27
Metformin Approved Phase 4 657-24-9 14219 4091
28
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
29
Hydroxychloroquine Approved Phase 4 118-42-3 3652
30
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
31
Lenvatinib Approved, Investigational Phase 4 417716-92-8
32
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
33
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
34
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
35
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
36 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
37
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
38
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
39
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
40
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
41
Mycophenolic acid Approved Phase 4 24280-93-1 446541
42
Methadone Approved Phase 4 76-99-3 4095
43
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
44 Vedolizumab Approved Phase 4 943609-66-3
45
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
46
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
47
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
48
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
49
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
50
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2

Interventional clinical trials:

(show top 50) (show all 2049)
# Name Status NCT ID Phase Drugs
1 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
2 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
3 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
4 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
5 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
6 Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults. Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
7 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
8 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
9 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
10 The Changes of Natural Killer Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B. Unknown status NCT03208998 Phase 4 Peginterferon Alfa-2a
11 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
12 Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
13 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Plus Adefovir Combination Treatment for Patients Previously Treated in EXPLORE, EXCEL and EFFORT Ex Study Unknown status NCT01834508 Phase 4 oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
14 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
15 The Changes of CD8+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209037 Phase 4 Peginterferon Alfa-2a
16 The Changes of CD4+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209011 Phase 4 Peginterferon Alfa-2a
17 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
18 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
19 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
20 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
21 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
22 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
23 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
24 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
25 Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients Unknown status NCT03332329 Phase 4 Entecavir;Granulocyte Macrophage Colony Stimulating Factor;Y peginterferon alfa-2b;HBV vaccine
26 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
27 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
28 The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B Unknown status NCT03349008 Phase 4 Entecavir;Magnesium Isoglycyrrhizinate;Diammonium Glycyrrhizinate;Magnesium Isoglycyrrhizinate Placebo;Diammonium Glycyrrhizinate Placebo
29 A Multicenter, Randomized, Open-label Control Study to Evaluate Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients Unknown status NCT03448744 Phase 4 Thymosin Alpha1;Entecavir
30 A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy Unknown status NCT02594293 Phase 4 PegIFN alfa-2a
31 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection. Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
32 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
33 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
34 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
35 Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a Unknown status NCT02368288 Phase 4 entecavir
36 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
37 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
38 HBsAg Clearance of Peginterferon Treatment in Patients Who Had Chronic Hepatitis B and Were on the Treatment of Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
39 Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment Unknown status NCT01491295 Phase 4 Tenofovir disoproxil fumarate;Lamivudine plus adefovir
40 A 3-year, Open-label, Multi-center Extension Trial of Telbivudine Therapy for Patients Previously Treated in EFFORT Clinical Trial Unknown status NCT01529255 Phase 4 telbivudine (ROADMAP);Telbivudine (Standard of Care)
41 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection Unknown status NCT03253250 Phase 4 ETV;TDF;ADV;Peginterferon Alfa-2a
42 The Optimizing Treatment of Peginterferon Alpha in HBeAg-negative Chronic Hepatitis B Virus Patients With Low Level HBsAg Unknown status NCT02893124 Phase 4 peginterferon alfa
43 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
44 A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml. Unknown status NCT02894918 Phase 4 Peginterferon alfa-2a
45 HBsAg Loss/Seroconversion in Low Replicative Chronic HBV Infection Patients With Low Level HBsAg Treated With Peginterferon Alpha Unknown status NCT02908763 Phase 4 peginterferon alfa
46 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
47 Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4 Entecavir and peginterferon (Pegasys) (52 weeks);Peginterferon (Pegasys) (96 weeks);Peginterferon (Pegasys) (48 weeks)
48 Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
49 A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
50 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)

Search NIH Clinical Center for Hepatitis B

Inferred drug relations via UMLS 71 / NDF-RT 50 :


adefovir
adefovir dipivoxil
entecavir
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
Interferon Alfa-2b
Lamivudine
telbivudine
Tenofovir
tenofovir alafenamide fumarate
Tenofovir disoproxil fumarate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis B cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis B:
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Hepatitis B:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: hepatitis b

Genetic Tests for Hepatitis B

Anatomical Context for Hepatitis B

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis B:

19
Liver

MalaCards organs/tissues related to Hepatitis B:

40
Liver, Testes, T Cells, Kidney, Bone, B Cells, Bone Marrow

Publications for Hepatitis B

Articles related to Hepatitis B:

(show top 50) (show all 32609)
# Title Authors PMID Year
1
Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma. 42 61
32443384 2020
2
Comparative efficacy of the front-line anti-HBV drugs in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and network meta-analysis. 42
32384507 2020
3
Bioinformatics analysis of key biomarkers and potential molecular mechanisms in hepatocellular carcinoma induced by hepatitis B virus. 42
32443377 2020
4
Effect of maternal hepatitis B carrier status on first-trimester markers of Down syndrome. 61 54
20332164 2010
5
Plasma levels of trace elements have an implication on interferon treatment of children with chronic hepatitis B infection. 61 54
19727570 2010
6
Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. 54 61
20304099 2010
7
Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. 54 61
20155784 2010
8
Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma. 54 61
20209613 2010
9
Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. 54 61
20107884 2010
10
Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? 61 54
20162620 2010
11
Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. 54 61
20070399 2010
12
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. 54 61
20091678 2010
13
Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. 61 54
20022949 2010
14
A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. 54 61
20137825 2010
15
Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. 54 61
19857525 2010
16
The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. 54 61
20053744 2010
17
Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. 54 61
19900483 2010
18
NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. 54 61
20010875 2010
19
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. 54 61
20101751 2010
20
Occult hepatitis B virus infection: a covert operation. 61 54
20002296 2010
21
Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. 54 61
20030580 2010
22
Nutritional status of children with chronic hepatitis B in a population with low socioeconomic status. 61 54
19458532 2009
23
Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma. 61 54
19626651 2009
24
Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. 54 61
19585616 2009
25
[Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment]. 61 54
19785947 2009
26
The correlation of hepatocyte nuclear factor 4 alpha and 3 beta with hepatitis B virus replication in the liver of chronic hepatitis B patients. 61 54
19302415 2009
27
Household survey of hepatitis B vaccine coverage among Brazilian children. 54 61
19616495 2009
28
Antiviral therapy for chronic hepatitis B: are we doing any good to patients? 54 61
19468026 2009
29
Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. 61 54
19263472 2009
30
Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. 61 54
19105208 2009
31
[Hepatitis B virus X protein upregulates the transcription activity of zinc finger transcription factor SNAI1]. 54 61
19671315 2009
32
Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. 54 61
19220736 2009
33
Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. 61 54
19208347 2009
34
Gene expression profiles of human liver cells mediated by hepatitis B virus X protein. 54 61
19343061 2009
35
CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients. 61 54
19403062 2009
36
[Dynamic changes of Th1/Th2 type cytokines in peripheral blood of patients with hepatitis B e antigen-positive chronic hepatitis B treated with telbivudine]. 54 61
19335978 2009
37
Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. 54 61
18662281 2009
38
Hepatitis B therapy in children. 61 54
19210112 2009
39
[Expression of interleukin-17 in hepatitis B related liver fibrosis]. 61 54
19174010 2009
40
Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. 61 54
20032548 2009
41
Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. 54 61
19812443 2009
42
Bicyclol: a novel drug for treating chronic viral hepatitis B and C. 54 61
19149648 2009
43
[A noninvasive model to predict histological liver cirrhosis in patients with chronic hepatitis B]. 61 54
19203448 2009
44
A review of the natural history of chronic hepatitis B in the era of transient elastography. 61 54
19578234 2009
45
Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. 61 54
19704174 2009
46
The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients' prognosis and hepatitis B virus X protein. 61 54
18465238 2008
47
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. 61 54
19052126 2008
48
Clinical, biochemical, immunological and virological profiles of, and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute flare. 61 54
18823435 2008
49
Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. 61 54
18840078 2008
50
Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway. 61 54
18801734 2008

Variations for Hepatitis B

Expression for Hepatitis B

Search GEO for disease gene expression data for Hepatitis B.

Pathways for Hepatitis B

GO Terms for Hepatitis B

Cellular components related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 TNF MIR301A MIR21 MIR17 MBL2 IFNA2

Biological processes related to Hepatitis B according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.84 TNF IFNAR2 IFNA2 IFNA1
2 defense response to virus GO:0051607 9.71 IFNAR2 IFNA2 IFNA1 APOBEC3G
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 TNF MIR21 F2
4 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.65 TNF MIR17 LAMTOR5
5 type I interferon signaling pathway GO:0060337 9.61 IFNAR2 IFNA2 IFNA1
6 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.52 TNF MIR21
7 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.51 TNF LAMTOR5
8 humoral immune response GO:0006959 9.5 TNF IFNA2 IFNA1
9 positive regulation of metalloendopeptidase activity GO:1904685 9.46 MIR21 MIR17
10 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.37 MIR21 MIR17
11 positive regulation of phagocytosis GO:0050766 9.33 TNF MIR17 MBL2
12 negative regulation of viral process GO:0048525 9.26 MBL2 APOBEC3G
13 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.13 TNF MIR21 MIR17
14 positive regulation of vascular smooth muscle cell proliferation GO:1904707 8.92 TNF MIR301A MIR21 MIR17

Sources for Hepatitis B